Molecular predictive and prognostic markers in colon cancer - PubMed

Review

Molecular predictive and prognostic markers in colon cancer

Thomas Winder et al. Cancer Treat Rev. 2010 Nov.

Abstract

Colorectal cancer remains one of the major cancer related death despite progress in the cytotoxic treatment of colorectal cancer (CRC) over the past decade. The introduction of targeted agents has improved the progression free and overall survival of metastatic disease. However, 40-50% of patients do not experience beneficial effects and it remains a challenge to select patients likely to respond to therapy. Several new molecular predictive and prognostic markers have been identified and are now being translated into routine clinical practice. K-Ras mutation is the first established molecular marker with a lack of response in K-Ras mutated patients treated with an epidermal growth factor receptor (EGFR)-targeted therapy. The validation of predictive and prognostic markers will result in more successful and less toxic therapeutic regimens for cancer patients. This review aims to summarize the most important currently available predictive and prognostic molecular markers in colorectal cancer.

Similar articles

• Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

  Grem JL. Grem JL. Semin Oncol. 2005 Feb;32(1):120-7. doi: 10.1053/j.seminoncol.2004.09.027. Semin Oncol. 2005. PMID: 15726514 Review.

• [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].

  Laurent-Puig P, Lièvre A, Ducreux M, Loriot MA. Laurent-Puig P, et al. Bull Cancer. 2008 Oct;95(10):935-42. doi: 10.1684/bdc.2008.0728. Bull Cancer. 2008. PMID: 19004723 French.

• Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

  Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY. Yen LC, et al. Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96. Ann Surg. 2010. PMID: 20010090

• Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.

  Allen WL, Johnston PG. Allen WL, et al. Pharmacogenomics. 2005 Sep;6(6):603-14. doi: 10.2217/14622416.6.6.603. Pharmacogenomics. 2005. PMID: 16143000 Review.

• Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.

  Bhushan S, McLeod H, Walko CM. Bhushan S, et al. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. doi: 10.3816/CCC.2009.n.003. Clin Colorectal Cancer. 2009. PMID: 19203892 Review.

Cited by

• Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.

  Yi K, Park SH, Kim DU, Jeon DY, Lee HJ, Song GA, Jo HJ, Baek DH, Han JH, Lee BC. Yi K, et al. In Vivo. 2023 Jul-Aug;37(4):1751-1759. doi: 10.21873/invivo.13263. In Vivo. 2023. PMID: 37369516 Free PMC article.

• Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

  Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Schwarz RE, et al. HPB (Oxford). 2013 Feb;15(2):106-15. doi: 10.1111/j.1477-2574.2012.00558.x. Epub 2012 Sep 24. HPB (Oxford). 2013. PMID: 23297721 Free PMC article.

• Molecular events in primary and metastatic colorectal carcinoma: a review.

  Kanthan R, Senger JL, Kanthan SC. Kanthan R, et al. Patholog Res Int. 2012;2012:597497. doi: 10.1155/2012/597497. Epub 2012 May 9. Patholog Res Int. 2012. PMID: 22997602 Free PMC article.

• Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer.

  Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Ochiai T, et al. Oncol Lett. 2011 Mar;2(2):309-313. doi: 10.3892/ol.2011.251. Epub 2011 Jan 21. Oncol Lett. 2011. PMID: 22866082 Free PMC article.

• Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.

  Wang J, Ma ZB, Li K, Guo GH. Wang J, et al. Med Oncol. 2014 Mar;31(3):874. doi: 10.1007/s12032-014-0874-y. Epub 2014 Feb 2. Med Oncol. 2014. PMID: 24488618

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal